CSL Income from Continuous Operations 2017-2024 | CSLLY

CSL income from continuous operations for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CSL annual income from continuous operations for 2024 was $2.714B, a 20.94% increase from 2023.
  • CSL annual income from continuous operations for 2023 was $2.244B, a 0.49% decline from 2022.
  • CSL annual income from continuous operations for 2022 was $2.255B, a 5.05% decline from 2021.

CSL Income from Continuous Operations 2017-2024 | CSLLY

  • CSL annual income from continuous operations for 2024 was $2.714B, a 20.94% increase from 2023.
  • CSL annual income from continuous operations for 2023 was $2.244B, a 0.49% decline from 2022.
  • CSL annual income from continuous operations for 2022 was $2.255B, a 5.05% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$217.3B
Amgen (AMGN)$160.8B
Gilead Sciences (GILD)$136.6B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$78.4B
Regeneron Pharmaceuticals (REGN)$59.2B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$35.4B
BioNTech SE (BNTX)$27B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.8B
Illumina (ILMN)$15.3B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$14B
Incyte (INCY)$13.4B
Moderna (MRNA)$12.4B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.1B
Roivant Sciences (ROIV)$7.8B
Regencell Bioscience Holdings (RGC)$7.6B
Legend Biotech (LEGN)$7.3B